New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
06:10 EDTAZN, DTVStocks with implied volatility below IV index mean; AZN DTV
Stocks with implied volatility below IV index mean; AstraZeneca (AZN) 25, DirecTV (DTV) 14.
News For AZN;DTV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 28, 2014
17:01 EDTAZNOn The Fly: Closing Wrap
Stocks on Wall Street opened in positive territory despite two disappointing economic data points and a mixed report from social media giant Twitter (TWTR). The market moved in a narrow range for the opening half hour of trading but gained upside momentum following a much better than expected consumer confidence reading. The market continued to tack on points throughout the afternoon and closed at its highs, led by the Nasdaq, which gained 1.75% for the session. ECONOMIC EVENTS: In the U.S., durable goods orders fell 1.3% in September, significantly undershooting expectations for them to have rise 0.7% in the month. The S&P Case-Shiller home price report showed prices were lower on a seasonally adjusted basis in the month of August compared to the prior month. A reading of consumer confidence surged to a seven-year high of 94.5 in October from a revised 89.0 final reading for September. The Richmond Fed's manufacturing index rose 6 points to 20 in October, beating expectations for it to have pulled back to 10. COMPANY NEWS: Twitter (TWTR) sunk $4.78, or 9.84%, to $43.78 after the social media company reported in-line profit and higher than expected Q3 revenue, but also reported a slowdown in user growth and provided weaker than expected Q4 guidance. Following last night's report, the stock was downgraded at RBC Capital, Nomura and Bank of America Merill Lynch to "Hold" or equivalent ratings, while Stifel lowered its rating on Twitter shares to Sell from Hold... Shares of Pfizer (PFE) edged up 6c, or 0.21%, to $29.09 after the pharmaceutical giant reported third quarter adjusted earnings per share and revenue that were a bit better than expected and narrowed its fiscal year profit outlook. Of note, Pfizer said during its earnings conference call that while proposed rule changes have made "inversions" more difficult, that meaningful value from inversion deals can still exists on a "case-by-case" basis. Shares of AstraZeneca (AZN), which was previously a target of Pfizer, gained 67c, or 0.95%, to $71.43 following Pfizer's comments. MAJOR MOVERS: Among the notable gainers following their earnings reports were Whirlpool (WHR), which advanced $10.66, or 6.77%, to $168.06, Cummins (CMI), which gained $9.22, or 6.81%, to $144.59, and Cliffs Natural (CLF), which jumped $2.05, or 22.19%, to $11.29. Among the noteworthy losers was Kohl’s (KSS), which dropped $3.89, or 6.64%, to $54.66 after the department store operator’s outlook for third quarter same store sales and fiscal 2014 profit missed expectations. Also lower were shares of Coach (COH), which fell $2.15, or 5.95%, to $34.00 after the luxury handbag and accessory maker reported sales declined 9% on a constant currency basis in its first quarter. INDEXES: The Dow rose 187.81, or 1.12%, to 17,005.75, the Nasdaq advanced 78.36, or 1.75%, to 4,564.29, and the S&P 500 gained 23.42, or 1.19%, to 1,985.05.
13:09 EDTDTVOptions with increasing implied volatility
Subscribe for More Information
12:57 EDTAZNOn The Fly: Midday Wrap
Subscribe for More Information
10:23 EDTAZNPfizer says still looking at deals based on strategic fit
Pfizer (PFE) said during its earnings conference call that uncertainty around future tax actions remain a concern, but that the company is still looking for M&A opportunities. Pfizer says proposed rule changes have made "inversions" more difficult, but that meaningful value from inversion deals can still exists on a "case-by-case" basis. Shares of AstraZeneca (AZN), which was previously a target of Pfizer, are up 1.3% to $71.69 as Pfizer's earnings conference call continues.
October 27, 2014
20:54 EDTAZNLeerink's major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
15:18 EDTAZNEarnings Preview: Pfizer looks to new products to offset generic competition
Subscribe for More Information
07:29 EDTAZNWorldwide Business Research to hold a conference
ProcureCon Pharma 2014 is being held in Philadelphia on October 27-29.
07:22 EDTAZNAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 24, 2014
12:38 EDTDTVFCC delays incentive auction until early 2016
Subscribe for More Information
06:49 EDTAZNPfizer repurchase could squash AstraZeneca bid goal, Reuters says
Subscribe for More Information
October 22, 2014
18:34 EDTDTVOn The Fly: After Hours Movers
UP AFTER EARNINGS: Select Comfort (SCSS), up 13.1% after reporting third quarter results and increasing share repurchase authorization to $250M... Infinera (INFN), up 9.8%... Tractor Supply (TSCO), up 11.8%... Acacia Research (ACTG), up 7.7%... Marketo (MKTO), up 4.5%... O'Reilly Automotive (ORLY), up 3.9%... Fortinet (FTNT), up 1.5%... Mellanox (MLNX), up 2.9%... ServiceNow (NOW), up just under 1%. ALSO HIGHER: CarMax (KMX), up 1% after announcing a $2B increase to its share repurchase program. DOWN AFTER EARNINGS: Air Methods (AIRM), down 19.8% following preliminary third quarter results... Yelp (YELP), down 13.6%... Core Laboratories (CLB), down 7.9%... Varian Medical (VAR), down 4.9% after reporting fourth quarter results... Open Text (OTEX), down 3.9%... Citrix (CTXS), down 5.7%... Cheesecake Factory (CAKE), down 4.5%... Allied World (AWH), down 4.7%... Lam Research (LRCX), down 3.3%... Skechers (SKX), down just under 1% after reporting third quarter results above analyst estimates... AT&T (T), down 1.5%. ALSO LOWER: DIRECTV (DTV), down just under 1% following AT&T third quarter results... Alcobra (ADHD), down 16% following results of MDX study... WidePoint (WYY), down 8.1% after filing an automatic common stock shelf... New Mountain Finance (NMFC), down 4.4% after filing to sell 5M shares of common stock.
11:12 EDTDTVFCC stops 'informal clock' for review of AT&T, Comcast proposed deals
Federal Communications Commission disclosed in a notice on its website that a number of commenters filed a motion for an extension of time to file replies in Docket 14-57, which is the review of the application of Comcast (CMCSA) for approval of its proposed acquisition of Time Warner Cable (TWC). Among other points, the commenters argue that certain third-party programmers “do not want any of the interested parties’ outside counsel or experts to view [their programming contracts],” the FCC noted. "We agree with these commenters that their current inability to review Highly Confidential Information that has been submitted in these dockets significantly hampers their ability to meaningfully comment and participate in these proceedings, in both Docket 14-57 and Docket 14-90. Accordingly, we are suspending the pleading cycles and stopping our 180-day informal time clock in both dockets," the FCC stated. Docket 14-90 refers to AT&T's (T) proposed purchase of DIRECTV (DTV). Reference Link
07:35 EDTAZNCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 21, 2014
13:09 EDTDTVEarnings Preview: AT&T to benefit from strong iPhone 6 demand, Wells Fargo says
AT&T (T) is expected to report third quarter earnings after the market close on Wednesday, October 22, with a conference call scheduled for 4:30 pm ET. AT&T is a global telecommunications company offering wireless and long distance services. EXPECTATIONS: Analysts are looking for earnings per share of 64c on revenue of $33.24B, according to First Call. The consensus range for EPS is 59c-66c on revenue of $31.77B-$34.34B. LAST QUARTER: AT&T reported second quarter EPS of 62c against estimates for 63c on revenue of $32.6B against estimates for $33.22B. On its Q2 earnings report, the company forecast FY14 EPS growth at the low end of a mid-single digit range, compared to consensus of $2.62. It sees: FY14 consolidated revenue growth in the 5% range, versus consensus $133.93B; FY14 free cash flow in the $11B range; FY14 capital expenditures remaining in the $21B range. In Q2, AT&T reported the following: total branded smartphone net adds, both postpaid and prepaid, of 576,000; total branded tablet net adds of 250,000; 366,000 postpaid tablet net adds; postpaid churn of 0.86%. On September 25, DirecTV (DTV) stockholders voted overwhelmingly to approve DIRECTV’s proposed merger with AT&T. STREET RESEARCH: Street research has been light in the weeks leading up to AT&T's Q3 earnings report. On September 15, Wells Fargo said AT&T should particularly benefit from strong Apple (AAPL) iPhone 6 demand. After Apple reported that over 4M iPhone 6 units were pre-ordered in the first 24 hours of eligibility, Wells Fargo said that it believed strong demand for the phones will be positive for all of the wireless carriers, but particularly for AT&T because of its strategic decision to focus on its early upgrade "Next!" program. The firm maintained its Outperform rating on AT&T. PRICE ACTION: AT&T’s shares have fallen approximately 4% since the company's Q2 report, but they did manage to make a 52-week high of $37.48 in late July. In afternoon trading ahead of tomorrow’s Q3 report, AT&T’s shares are up 0.5%.
07:15 EDTAZNFDA to hold workshop on breast cancer drug development
Subscribe for More Information
06:10 EDTAZNInovio, MedImmune, UPENN awarded $12.2M collaborative study by DARPA
Inovio Pharmaceuticals (INO) announced the Defense Advanced Research Projects Agency, or DARPA, has awarded $12.2M for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The group will develop DNA-based monoclonal antibodies, or mAbs, for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security. Together, the three organizations will develop and assess the DNA mAbs in preclinical studies using technology developed by Penn and licensed by Inovio. The collaboration will focus on three disease areas – influenza virus, Pseudomonas aeruginosa and Staphylococcus aureus.
October 20, 2014
07:47 EDTAZNPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:19 EDTAZNIBC Life Sciences to hold a conference
Subscribe for More Information
07:14 EDTAZNEuropean College of Neuropsychopharmacology to hold a conference
27th ECNP Congress is being held in Berlin, Germany on October 18-21.
October 17, 2014
10:51 EDTDTVOptions with increasing implied volatility
Options with increasing implied volatility: COV DISH HLT QEP GREK BKW BYI LLY DTV TIBX
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use